Assessing eye movements in Parkinson's Disease
Official title: Ocular Microtremor in Parkinson's Disease
Run by Northumbria University · NCT06051877 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing if a new handheld device can measure tiny eye movements in people with Parkinson's Disease to see if it can help understand their symptoms and improve their care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Northumbria University Academic / other |
| Locations | 2 sites (Gateshead, Tyne And Wear and 1 other locations) |
| Trial ID | NCT06051877 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with confirmed or suspected Parkinson's Disease, as well as healthy older adults for comparison.
✕Probably not a fit
Patients with psychiatric co-morbidities, significant head injuries, or ocular diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study explores ocular microtremor (OMT) as a potential biomarker for Parkinson's Disease (PD) using a handheld device called the iTremor ONE. Participants, including those with confirmed or suspected PD and healthy controls, will undergo home-based assessments to measure OMT frequency, cognitive function, and motor skills. The study will compare OMT readings in participants both on and off their anti-parkinsonian medication, with additional laboratory assessments for balance and gait. The aim is to establish a link between OMT and neurological function to enhance clinical assessment and care for PD patients.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic tools and monitoring methods for patients with Parkinson's Disease.
How similar studies have gone: While the use of ocular microtremor as a biomarker is a novel approach, similar studies have shown promise in linking eye movements to neurological conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * People with suspected PD * People with confirmed PD * Healthy controls * No history of head trauma Exclusion Criteria: * PD and older adult participants will be excluded if there is any psychiatric co-morbidity, * a history or evidence of head injury or ocular disease (such as cataracts), * they have a clinical diagnosis of dementia or other severe cognitive impairment (measured using the MoCA with a score of \<21).
Where it's running
-
Northumbria Healthcare NHS Trust
North Shields, Tyne And Wear, United Kingdom Recruiting -
Gateshead Health NHS Foundation Trust
Gateshead, Tyne And Wear, United Kingdom Not yet recruiting
Study contacts
- Principal investigator: Samuel Stuart, PhD — Employee
- Study coordinator: Lisa Graham, BSc
- Email: lisa4.graham@northumbria.ac.uk
- Phone: +44 7972257940
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
-
Long-Term Safety and Durability of IPS101A in Parkinson's Disease
This long-term follow-up checks if IPS101A continues to be safe and whether its benefits last for people with Parkinson's who previously received the treatment.
-
IPS101A AAV gene therapy for advanced Parkinson's disease
This Phase 1 test will see if IPS101A, an AAV gene therapy, is safe and helps people aged 50–80 with advanced Parkinson's (Hoehn & Yahr 4–5) whose symptoms are not controlled by standard treatments.
-
Detecting Parkinson's-related alpha-synuclein in colon tissue taken during routine colonoscopy
This will see if small extra colon tissue samples taken during a routine colonoscopy can find phosphorylated alpha-synuclein in people with Parkinson's disease or REM sleep behavior disorder.
-
Understanding serotonin release in Parkinson's disease
This study is trying to find a way to see changes in the brain of people with Parkinson's disease to help develop new treatments that could slow down the symptoms.
-
Investigating biomarkers for Parkinson's disease using advanced imaging techniques
This study is trying to find a marker for Parkinson's disease by using advanced brain scans to see how the disease affects brain chemistry and structure over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.